Enterprise Value
-107.5M
Cash
186.1M
Avg Qtr Burn
-21.95M
Short % of Float
2.94%
Insider Ownership
2.05%
Institutional Own.
68.99%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Fosgonimeton (ATH-1017) Details Alzheimer's disease | Phase 2/3 Data readout | |
Fosgonimeton (ATH-1017) Details Parkinson's disease, Dementia | Phase 2 Update |